Anti-TNF-α/CXCL10 double-targeting antibody and use thereof
US10087248B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 22, 2014 |
| Grant date | Oct 2, 2018 |
| Priority date | — |
| Expiry date | May 22, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a TNF-α (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-α specific antibody, is a bispecific antibody that effectively binds to both TNF-α and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-α/CXCL10. A composition of the present invention comprises a TNF-α/CXCL-10 double targeting antibody which effectively binds to both TNF-α and CXCL10. The double targeting antibody of the present invention has excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-α or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.